Clinical Trial Update: Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating capecitabine for HER2-positive breast cancer with residual disease after preoperative chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN